TheraRadar
← Back
Data updated: Jun 28, 2026

JIANGXI KVVIT PHARM

Generics

JIANGXI KVVIT PHARM is a generic drug manufacturer focused on Oncology, Dermatology.

2024
Since
1
Drugs
-
Trials
0
New Drugs (2yr)

JIANGXI KVVIT PHARM's Key Drugs

JIANGXI KVVIT PHARM's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

JIANGXI KVVIT PHARM's Recent FDA Approvals

New NDA/BLA approvals for JIANGXI KVVIT PHARM over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

JIANGXI KVVIT PHARM's Therapeutic Areas

JIANGXI KVVIT PHARM's approved drugs and pipeline span 2 therapeutic areas, led by Oncology and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 75%
1 drugs
Dermatology 25%
0 drugs Phase 2: 1

JIANGXI KVVIT PHARM's Top Competitors

JIANGXI KVVIT PHARM's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Baxter, and Eli Lilly. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

JIANGXI KVVIT PHARM Pipeline Snapshot

JIANGXI KVVIT PHARM has 1 active clinical program from ClinicalTrials.gov — 0 Phase 3, 1 Phase 2 and 0 Phase 1.

0
Phase 3
1
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling